Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments

British Journal of Pharmacology

Volumn 165, Issue 2, 2012, Pages 424-435

  Elhabazi, K ^a   Trigo, J M ^b   Mollereau, C ^c   Mouledous L ^c   Zajac, J M ^c   Bihel, F ^a   Schmitt, M ^a   Bourguignon, J J ^a   Meziane, H ^d   Petit Demouliere B ^d   Bockel, F ^e   Maldonado, R ^b   Simonin, Frédéric Simonin ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c UNIVERSITÉ DE TOULOUSE   (France)

^d INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^e Phenopro   (France)

Author keywords

anti opioid system; morphine tolerance; NPFF receptors; opioid induced hyperalgesia; reward; RF9; RFamide; withdrawal dependence

Indexed keywords

FENTANYL; MORPHINE; NALTREXONE; NEUROPEPTIDE FF RECEPTOR; NEUROPEPTIDE RECEPTOR; OPIATE; RECEPTOR BLOCKING AGENT; RF 9; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERANCE; HYPERALGESIA; LOCOMOTION; MALE; MOUSE; NONHUMAN; OPIATE ADDICTION; OPIOID INDUCED HYPERALGESIA; PLACE PREFERENCE; PRIORITY JOURNAL; RECEPTOR BLOCKING; REWARD; WITHDRAWAL SYNDROME;

ADAMANTANE; ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ANIMAL; CONDITIONING, CLASSICAL; DIPEPTIDES; DRUG TOLERANCE; FENTANYL; HOT TEMPERATURE; HYPERALGESIA; MALE; MICE; MICE, INBRED C57BL; MORPHINE; MOTOR ACTIVITY; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PAIN; RECEPTORS, NEUROPEPTIDE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 83755205434     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01563.x     Document Type: Article

References (48)

1. Calo G, Guerrini R, Bigoni R, Rizzi A, Marzola G, Okawa H, et al,. (2000). Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist. Br J Pharmacol 129: 1183-1193. (Pubitemid 30153975)
2. Celerier E, Rivat C, Jun Y, Laulin JP, Larcher A, Reynier P, et al,. (2000). Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. Anesthesiology 92: 465-472. (Pubitemid 30078345)
3. Celerier E, Simonnet G, Maldonado R, (2004). Prevention of fentanyl-induced delayed pronociceptive effects in mice lacking the protein kinase Cgamma gene. Neuropharmacology 46: 264-272. (Pubitemid 37532834)
4. Dourish CT, O'Neill MF, Coughlan J, Kitchener SJ, Hawley D, Iversen SD, (1990). The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur J Pharmacol 176: 35-44. (Pubitemid 20035551)
5. Drdla R, Gassner M, Gingl E, Sandkuhler J, (2009). Induction of synaptic long-term potentiation after opioid withdrawal. Science 325: 207-210.
6. Gelot A, Frances B, Gicquel S, Zajac JM, (1998). Antisense oligonucleotides to human SQA-neuropeptide FF decrease morphine tolerance and dependence in mice. Eur J Pharmacol 358: 203-206. (Pubitemid 28498179)
7. Gouarderes C, Puget A, Zajac JM, (2004). Detailed distribution of neuropeptide FF receptors (NPFF1 and NPFF2) in the rat, mouse, octodon, rabbit, guinea pig, and marmoset monkey brains: a comparative autoradiographic study. Synapse 51: 249-269. (Pubitemid 38140898)
8. Guignard B, Bossard AE, Coste C, Sessler DI, Lebrault C, Alfonsi P, et al,. (2000). Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology 93: 409-417. (Pubitemid 30620314)
9. Idanpaan-Heikkila JJ, Guilbaud G, Kayser V, (1997). Prevention of tolerance to the antinociceptive effects of systemic morphine by a selective cholecystokinin-B receptor antagonist in a rat model of peripheral neuropathy. J Pharmacol Exp Ther 282: 1366-1372. (Pubitemid 27408317)
10. Jhamandas JH, Simonin F, Bourguignon JJ, Harris KH, (2007). Neuropeptide FF and neuropeptide VF inhibit GABAergic neurotransmission in parvocellular neurons of the rat hypothalamic paraventricular nucleus. Am J Physiol Regul Integr Comp Physiol 292: R1872-R1880. (Pubitemid 46708542)
11. Kersante F, Mollereau C, Zajac JM, Roumy M, (2006). Anti-opioid activities of NPFF1 receptors in a SH-SY5Y model. Peptides 27: 980-989.
12. Kieffer BL, Evans CJ, (2002). Opioid tolerance-In search of the holy grail. Cell 108: 587-590. (Pubitemid 34241419)
13. Kotlinska J, Pachuta A, Dylag T, Silberring J, (2007). Neuropeptide FF (NPFF) reduces the expression of morphine-but not of ethanol-induced conditioned place preference in rats. Peptides 28: 2235-2242. (Pubitemid 47600409)
14. Kotlinska J, Pachuta A, Silberring J, (2008). Neuropeptide FF (NPFF) reduces the expression of cocaine-induced conditioned place preference and cocaine-induced sensitization in animals. Peptides 29: 933-939.
15. Lake JR, Hammond MV, Shaddox RC, Hunsicker LM, Yang HY, Malin DH, (1991). IgG from neuropeptide FF antiserum reverses morphine tolerance in the rat. Neurosci Lett 132: 29-32.
16. Lake JR, Hebert KM, Payza K, Deshotel KD, Hausam DD, Witherspoon WE, et al,. (1992). Analog of neuropeptide FF attenuates morphine tolerance. Neurosci Lett 146: 203-206.
17. Maldonado R, Saiardi A, Valverde O, Samad TA, Roques BP, Borrelli E, (1997). Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature 388: 586-589. (Pubitemid 27340008)
18. Malin DH, Lake JR, Hammond MV, Fowler DE, Rogillio RB, Brown SL, et al,. (1990). FMRF-NH2-like mammalian octapeptide: possible role in opiate dependence and abstinence. Peptides 11: 969-972. (Pubitemid 20337193)
19. Malin DH, Lake JR, Smith DA, Jones JA, Morel J, Claunch AE, et al,. (1995). Subcutaneous injection of an analog of neuropeptide FF prevents naloxone-precipitated morphine abstinence syndrome. Drug Alcohol Depend 40: 37-42.
20. Mao J, (1999). NMDA and opioid receptors: their interactions in antinociception, tolerance and neuroplasticity. Brain Res Rev 30: 289-304. (Pubitemid 29531489)
21. Mao J, Price DD, Mayer DJ, (1995). Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 62: 259-274.
22. Marchand S, Betourne A, Marty V, Daumas S, Halley H, Lassalle JM, et al,. (2006). A neuropeptide FF agonist blocks the acquisition of conditioned place preference to morphine in C57Bl/6J mice. Peptides 27: 964-972.
23. Marco N, Stinus L, Allard M, Le Moal M, Simonnet G, (1995). Neuropeptide FLFQRFamide receptors within the ventral mesenchephalon and dopaminergic terminal areas: localization and functional antiopioid involvement. Neuroscience 64: 1035-1044.
24. Max MB, Stewart WF, (2008). The molecular epidemiology of pain: a new discipline for drug discovery. Nat Rev Drug Discov 7: 647-658.
25. McNally GP, (1999). Pain facilitatory circuits in the mammalian central nervous system: their behavioral significance and role in morphine analgesic tolerance. Neurosci Biobehav Rev 23: 1059-1078.
26. Mollereau C, Roumy M, Zajac JM, (2005a). Opioid-modulating peptides: mechanisms of action. Curr Top Med Chem 5: 341-355. (Pubitemid 40614134)
27. Mollereau C, Mazarguil H, Zajac JM, Roumy M, (2005b). Neuropeptide FF (NPFF) analogs functionally antagonize opioid activities in NPFF2 receptor-transfected SH-SY5Y neuroblastoma cells. Mol Pharmacol 67: 965-975. (Pubitemid 40365344)
28. Mouledous L, Mollereau C, Zajac JM, (2010). Opioid-modulating properties of the neuropeptide FF system. Biofactors 36: 423-429.
29. Randall LO, Selitto JJ, (1957). A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 111: 409-419.
30. Rebeyrolles S, Zajac JM, Roumy M, (1996). Neuropeptide FF reverses the effect of mu-opioid on Ca2+ channels in rat spinal ganglion neurones. Neuroreport 7: 2979-2981. (Pubitemid 26426373)
31. Rothman RB, (1992). A review of the role of anti-opioid peptides in morphine tolerance and dependence. Synapse 12: 129-138.
32. Roumy M, Zajac J, (1999). Neuropeptide FF selectively attenuates the effects of nociceptin on acutely dissociated neurons of the rat dorsal raphe nucleus. Brain Res 845: 208-214. (Pubitemid 29486460)
33. Roumy M, Garnier M, Zajac JM, (2003). Neuropeptide FF receptors 1 and 2 exert an anti-opioid activity in acutely dissociated rat dorsal raphe and periventricular hypothalamic neurones. Neurosci Lett 348: 159-162. (Pubitemid 36976830)
34. Rutten K, De Vry J, Bruckmann W, Tzschentke TM, (2011). Pharmacological blockade or genetic knockout of the NOP receptor potentiates the rewarding effect of morphine in rats. Drug Alcohol Depend 114: 253-256.
35. Scoto GM, Arico G, Iemolo A, Ronsisvalle G, Parenti C, (2010). Selective inhibition of the NOP receptor in the ventrolateral periaqueductal gray attenuates the development and the expression of tolerance to morphine-induced antinociception in rats. Peptides 31: 696-700.
36. Simonin F, (2006). Neuropeptide FF receptors as therapeutic targets. Drugs Future 31: 603-609. (Pubitemid 44594570)
37. Simonin F, Valverde O, Smadja S, Slowe S, Kitchen I, Dierich A, et al,. (1998). Disruption of the κ-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective κ-agonist U-50,488H and attenuates morphine withdrawal. EMBO J 17: 886-897. (Pubitemid 28077643)
38. Simonin F, Schmitt M, Laulin J-P, Laboureyras E, Jhamandas JH, MacTavish D, et al,. (2006). RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia. Proc Natl Acad Sci U S A 103: 466-471. (Pubitemid 43122424)
39. Simonnet G, Rivat C, (2003). Opioid-induced hyperalgesia: abnormal or normal pain? Neuroreport 14: 1-7. (Pubitemid 36160732)
40. Tan PP, Chen JC, Li JY, Liang KW, Wong CH, Huang EY, (1999). Modulation of naloxone-precipitated morphine withdrawal syndromes in rats by neuropeptide FF analogs. Peptides 20: 1211-1217. (Pubitemid 29512442)
41. Trigo JM, Zimmer A, Maldonado R, (2009). Nicotine anxiogenic and rewarding effects are decreased in mice lacking beta-endorphin. Neuropharmacology 56: 1147-1153.
42. Ueda H, (2004). Locus-specific involvement of anti-opioid systems in morphine tolerance and dependence. Ann N Y Acad Sci 1025: 376-382. (Pubitemid 39643884)
43. Ueda H, Ueda M, (2009). Mechanisms underlying morphine analgesic tolerance and dependence. Front Biosci 14: 5260-5672.
44. Wang YQ, Guo J, Wang SB, Fang Q, He F, Wang R, (2008). Neuropeptide FF receptors antagonist, RF9, attenuates opioid-evoked hypothermia in mice. Peptides 29: 1183-1190.
45. Wilson GR, Reisfield GM, (2003). Morphine hyperalgesia: a case report. Am J Hosp Palliat Care 20: 459-461. (Pubitemid 39387674)
46. Yang HY, Fratta W, Majane EA, Costa E, (1985). Isolation, sequencing, synthesis, and pharmacological characterization of two brain neuropeptides that modulate the action of morphine. Proc Natl Acad Sci U S A 82: 7757-7761. (Pubitemid 16204428)
47. Zeng Z, McDonald TP, Wang R, Liu Q, Austin CP, (2003). Neuropeptide FF receptor 2 (NPFF2) is localized to pain-processing regions in the primate spinal cord and the lower level of the medulla oblongata. J Chem Neuroanat 25: 269-278. (Pubitemid 36776778)
48. Zhou HY, Chen SR, Chen H, Pan HL, (2010). Opioid-induced long-term potentiation in the spinal cord is a presynaptic event. J Neurosci 30: 4460-4466.